title: A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro.
abstract: The epidermal growth factor receptor (EGFR) serves an important function in the proliferation of tumors in humans and is an effective target for the treatment of cancer. In this paper, we studied the targeting characteristics of small peptides (AEYLR, EYINQ, and PDYQQD) that were derived from three major autophosphorylation sites of the EGFR C-terminus domain in vitro. These small peptides were labeled with fluorescein isothiocyanate (FITC) and used the peptide LARLLT as a positive control, which bound to putative EGFR selected from a virtual peptide library by computer-aided design, and the independent peptide RALEL as a negative control. Analyses with flow cytometry and an internalization assay using NCI-H1299 and K562 with high EGFR and no EGFR expression, respectively, indicated that FITC-AEYLR had high EGFR targeting activity. Biotin-AEYLR that was specifically bound to human EGFR proteins demonstrated a high affinity for human non-small-cell lung tumors. We found that AEYLR peptide-conjugated, nanostructured lipid carriers enhanced specific cellular uptake in vitro during a process that was apparently mediated by tumor cells with high-expression EGFR. Analysis of the MTT assay indicated that the AEYLR peptide did not significantly stimulate or inhibit the growth activity of the cells. These findings suggest that, when mediated by EGFR, AEYLR may be a potentially safe and efficient delivery ligand for targeted chemotherapy, radiotherapy, and gene therapy.
authors.affiliation: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.
authors.forename: Cui-yan
authors.initials: CY
authors.lastname: Han
authors.forename: Li-ling
authors.initials: LL
authors.lastname: Yue
authors.forename: Ling-yu
authors.initials: LY
authors.lastname: Tai
authors.forename: Li
authors.initials: L
authors.lastname: Zhou
authors.forename: Xue-yan
authors.initials: XY
authors.lastname: Li
authors.forename: Gui-hua
authors.initials: GH
authors.lastname: Xing
authors.forename: Xing-gang
authors.initials: XG
authors.lastname: Yang
authors.forename: Ming-shuang
authors.initials: MS
authors.lastname: Sun
authors.forename: Wei-san
authors.initials: WS
authors.lastname: Pan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics*; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D020014:K562 Cells; D008175:Lung Neoplasms / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry / Q000493:pharmacokinetics* / Q000494:pharmacology; D011485:Protein Binding
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D009842:Oligopeptides; D066246:ErbB Receptors
keywords: EGFR; NLC; lung cancer; small peptide; tumor targeting